Hemostemix (CVE:HEM) Trading Down 22.9% – Here’s Why

Hemostemix Inc. (CVE:HEM) traded down 22.9% during mid-day trading on Thursday . The stock traded as low as C$0.18 and last traded at C$0.19. 504,239 shares traded hands during mid-day trading, a decline of 5% from the average session volume of 530,580 shares. The stock had previously closed at C$0.24.

Hemostemix Price Performance

The company has a market cap of C$26.96 million, a price-to-earnings ratio of -5.39 and a beta of 0.20. The company has a current ratio of 0.04, a quick ratio of 0.48 and a debt-to-equity ratio of -55.07. The business has a 50-day moving average price of C$0.19 and a 200 day moving average price of C$0.11.

Hemostemix Company Profile

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.